545 related articles for article (PubMed ID: 17253907)
1. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
[TBL] [Abstract][Full Text] [Related]
2. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
3. Torsade de pointes and low-dose oral haloperidol.
Jackson T; Ditmanson L; Phibbs B
Arch Intern Med; 1997 Sep; 157(17):2013-5. PubMed ID: 9308514
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
Metzger E; Friedman R
J Clin Psychopharmacol; 1993 Apr; 13(2):128-32. PubMed ID: 8463445
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol-induced torsade de pointes.
O'Brien JM; Rockwood RP; Suh KI
Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
[TBL] [Abstract][Full Text] [Related]
6. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
7. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
8. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
11. Sulpiride induced torsade de pointes.
Huang BH; Hsia CP; Chen CY
Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
Harvey AT; Flockhart D; Gorski JC; Greenblatt DJ; Burke M; Werder S; Preskorn SH
J Clin Pharmacol; 2004 Oct; 44(10):1173-84. PubMed ID: 15342619
[TBL] [Abstract][Full Text] [Related]
13. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
14. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
Ginwalla M; Biblo LA; Paydak H
WMJ; 2009 Feb; 108(1):48-50. PubMed ID: 19326637
[TBL] [Abstract][Full Text] [Related]
15. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
[TBL] [Abstract][Full Text] [Related]
16. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J
J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874
[TBL] [Abstract][Full Text] [Related]
17. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
Lawrence KR; Nasraway SA
Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
[TBL] [Abstract][Full Text] [Related]
18. Female preponderance in ibutilide-induced torsade de pointes.
Gowda RM; Khan IA; Punukollu G; Vasavada BC; Sacchi TJ; Wilbur SL
Int J Cardiol; 2004 Jun; 95(2-3):219-22. PubMed ID: 15193823
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
Cardiovasc Toxicol; 2017 Jul; 17(3):319-325. PubMed ID: 27738880
[TBL] [Abstract][Full Text] [Related]
20. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity.
Yamaguchi M; Shimizu M; Ino H; Terai H; Uchiyama K; Oe K; Mabuchi T; Konno T; Kaneda T; Mabuchi H
Clin Sci (Lond); 2003 Dec; 105(6):671-6. PubMed ID: 12857349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
